MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bicycle Therapeutics plc - American Depositary Shares (NQ:BCYC)

4.350 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 4.350
Bid (Size) 4.230 (100)
Ask (Size) 4.450 (200)
Prev. Close 4.350
Today's Range 4.350 - 4.350
52wk Range 3.920 - 9.183
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
From Bicycle Therapeutics plc
Via Business Wire

Performance

YTD
-34.9%
-34.9%
1 Month
+4.8%
+4.8%
3 Month
-12.7%
-12.7%
6 Month
-33.9%
-33.9%
1 Year
-46.2%
-46.2%

More News

Read More
News headline image
Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics Announces Oral and Poster Presentations at the AACR Annual Meeting 2026
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics Announces Leadership Transitions for Next Phase of Innovation Across Oncology Pipeline
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics Highlights 2025 Accomplishments and Strategic Priorities for 2026
From Bicycle Therapeutics plc
Via Business Wire
News headline image
The Great Migration: Why International Tech and Biotech Giants are Redomiciling to the Massachusetts Hub
Via MarketMinute
Topics Economy Initial Public Offering
News headline image
Bicycle Therapeutics Establishes Multiple Strategic Partnerships to Create End-to-End Supply Chain to Support its Wholly Owned Radiopharmaceutical Pipeline
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics Strengthens Board of Directors with New Appointments
From Bicycle Therapeutics plc
Via Business Wire
News headline image
4 Analysts Assess Bicycle Therapeutics: What You Need To Know ↗
Via Benzinga
News headline image
Bicycle (BCYC) Q2 Revenue Falls 69% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Demystifying Bicycle Therapeutics: Insights From 7 Analyst Reviews ↗
Via Benzinga
News headline image
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics Announces Poster Presentations at the 2025 ASCO Annual Meeting
From Bicycle Therapeutics
Via Business Wire
News headline image
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Bicycle Therapeutics plc
Via Business Wire
News headline image
A Glimpse Into The Expert Outlook On Bicycle Therapeutics Through 7 Analysts ↗
Via Benzinga
News headline image
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics Announces Presentation of Additional Human Radiopharmaceutical Imaging Data for MT1-MMP at the American Association for Cancer Research Annual Meeting 2025
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Analyst Expectations For Bicycle Therapeutics's Future ↗
Via Benzinga

Frequently Asked Questions

Is Bicycle Therapeutics plc - American Depositary Shares publicly traded?
Yes, Bicycle Therapeutics plc - American Depositary Shares is publicly traded.
What exchange does Bicycle Therapeutics plc - American Depositary Shares trade on?
Bicycle Therapeutics plc - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Bicycle Therapeutics plc - American Depositary Shares?
The ticker symbol for Bicycle Therapeutics plc - American Depositary Shares is BCYC on the Nasdaq Stock Market
What is the current price of Bicycle Therapeutics plc - American Depositary Shares?
The current price of Bicycle Therapeutics plc - American Depositary Shares is 4.350
When was Bicycle Therapeutics plc - American Depositary Shares last traded?
The last trade of Bicycle Therapeutics plc - American Depositary Shares was at 07/13/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story